We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+10.83%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$6.37B
AUM Growth
+$618M
Cap. Flow
+$498M
Cap. Flow %
7.82%
Top 10 Hldgs %
71.12%
Holding
53
New
7
Increased
13
Reduced
9
Closed
6

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$224M
2
XLRN
Acceleron Pharma
XLRN
+$131M
3
FOLD
Amicus Therapeutics
FOLD
+$53.5M
4
WHWK
Whitehawk Therapeutics
WHWK
+$46.6M
5
NUVL
Nuvalent
NUVL
+$36.5M

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$108M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$38.4M
3
RLMD icon
Relmada Therapeutics
RLMD
+$29.9M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$24.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLMA icon
51
Olema Pharmaceuticals
OLMA
$1.05B
– –
-876,986
Closed -$24.5M
RLMD icon
52
Relmada Therapeutics
RLMD
$550M
– –
-935,000
Closed -$29.9M
CNST
53
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-3,210,000
Closed -$108M
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Avoro Capital Advisors held 53 positions worth $6.37B, up 11% from $5.75B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Avoro Capital Advisors deployed $498M of net new capital in Q3 2021, opening 7 new positions and adding to 13 existing holdings. Its largest new stake was Nuvalent: 1,257,671 shares worth $22.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Arena Pharmaceuticals Inc, an estimated $38.4M trimmed.

  • Avoro Capital Advisors's largest Q3 2021 buy was Nuvalent: 1,257,671 shares worth $22.3M.
  • Avoro Capital Advisors added most to Apellis Pharmaceuticals in Q3 2021, an estimated $224M increase.
  • Avoro Capital Advisors's biggest Q3 2021 reduction was Arena Pharmaceuticals Inc, cutting an estimated $38.4M.
  • Avoro Capital Advisors fully exited Constellation Pharmaceuticals, Inc. in Q3 2021, selling an estimated $108M.
  • Avoro Capital Advisors's ten largest holdings make up 71% of its $6.37B portfolio in Q3 2021.
  • Avoro Capital Advisors opened 7 new positions and closed 6 in Q3 2021.
  • Avoro Capital Advisors's portfolio value rose 11% quarter-over-quarter to $6.37B.

Based on Avoro Capital Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.